Technical Service Need help? Our team of experienced experts is here for you with full support.
AKA-14
Olaparib
Cat. No.
AKA-14
CAS No.
763113-22-0
MF
C24H23FN4O3
MW
434.471
Olaparib is a small molecule inhibitor of PARP1/PARP2, with weak inhibitory activity against PARP tankyrase‑1.
Advanced Equipments & Extensive Production Expertise
Commercial Manufacturing
Stable Quality
Customization Supporting
Technical Service 
86-28-85159085 
info@aktin.com
Technical Data
Description
Storage and Shipping
References
Product Name
Olaparib
CAS No.
763113-22-0
MF
C24H23FN4O3
MW
434.471
Specification
99%
Research Area
Oncology
Description
Olaparib is a small molecule inhibitor of PARP1/PARP2, with weak inhibitory activity against PARP tankyrase‑1. Packing: 1kg/bag; 25kg/drum or as request Availability: In stock
Documents
Certificate of Analysis (COA), API specification, Safety Data Sheet (SDS/MSDS), evidence of GMP compliance, Stability data / Stability summary, etc.
Storage and Shipping
Store in a cool & dry place, keep away from strong light and heat.
References
[1]. Menear KA, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. Journal of Medicinal Chemistry. 2008 Oct 23;51(20):6581-91
[2]. Senra JM, et al. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.Molecular Cancer Therapeutics. 2011 Oct;10(10):1949-58.
[3]. Yasukawa M, et al. Synergetic Effects of PARP Inhibitor AZD2281 in Oral Squamous Cell Carcinoma in Vitro and in Vivo. International Journal of Molecular Sciences. 2016 Feb 24;17(3):272.
[4]. Bian X, et al. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene. 2018 Jan 18;37(3):341-351.
[2]. Senra JM, et al. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.Molecular Cancer Therapeutics. 2011 Oct;10(10):1949-58.
[3]. Yasukawa M, et al. Synergetic Effects of PARP Inhibitor AZD2281 in Oral Squamous Cell Carcinoma in Vitro and in Vivo. International Journal of Molecular Sciences. 2016 Feb 24;17(3):272.
[4]. Bian X, et al. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene. 2018 Jan 18;37(3):341-351.
Disclaimer
This product is intended solely for scientific research or regulatory filing purposes. We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Related Products
AKA-384
Tedizolid phosphate
CAS No.: 856867-55-5
MF:C17H16FN6O6P
AKA-383
Brivaracetam
CAS No.:357336-20-0
MF:C11H20N2O2
AKA-382
Cobimetinib Fumarate
CAS No.:1369665-02-0
MF:C46H46F6I2N6O8
AKA-379
Bempedoic acid
CAS No.:738606-46-7
MF:C19H36O5
AKA-378
Borofalan(10B)
CAS No.:80994-59-8
MF:C9H12BNO4
AKA-377
AkProva™ Metildigoxin
CAS No.:30685-43-9(acetone-free)
MF:C42H66O14.1/2C3H6O
AKA-376
AkProva™ beta-Acetyldigoxin
CAS No.:5355-48-6
MF:C43H66O15
AKA-375
Ak-NucleoVia™ Agrostemmoside E
CAS No.:2656438-29-6
MF:C84H128O45
AKA-374
Novobiocin sodium
CAS No.:1476-53-5
MF:C31H35N2NAO11
AKA-360
Travoprost
CAS No.:157283-68-6
MF:C26H35F3O6
* Some statements have not been evaluated by national authorities. * Some products are not intended to diagnose, treat, cure, or prevent any disease. * For literature supporting, please contact us directly.
